论文部分内容阅读
目的探讨达沙替尼(dasatinb)增强吉非替尼(gefitinib)对HCC827肺癌细胞杀伤作用的分子机制。方法单独(0、100、500、1000)nmol/L gefitinib及联合使用dasatinb(1000 nmol/L)处理HCC827细胞及gefitinib耐药株HCC827GR细胞,采用MTT法检测HCC827细胞、HCC827GR细胞增殖活力,采用分光光度法检测caspase 3活性,Western blot法检测各组细胞中Src、表皮生长因子受体(EGFR)蛋白磷酸化水平。结果 HCC827GR细胞中Src磷酸化水平显著增高,dasatinb显著抑制Src磷酸化水平,抑制细胞增殖并促进caspase 3表达,两种药物联合应用杀伤效果显著高于单纯gefitinib处理组。结论 Dasatinb与gefitinib联合应用可增强对Src家族表达的抑制,增强gefitinib对HCC827肺癌细胞的杀伤作用。
Objective To investigate the molecular mechanism of dasatinb enhancing the killing effect of gefitinib on HCC827 lung cancer cells. Methods The HCC827 cells and the gefitinib resistant HCC827GR cells were treated with nmol / L gefitinib alone and combined with dasatinb (1000 nmol / L). The proliferation of HCC827 cells and HCC827GR cells was detected by MTT assay. The activity of caspase 3 was detected by spectrophotometry. The phosphorylation of Src and epidermal growth factor receptor (EGFR) was detected by Western blot. Results The phosphorylation of Src in HCC827GR cells was significantly increased. Dasatinb significantly inhibited the phosphorylation of Src, inhibited cell proliferation and promoted the expression of caspase 3. The killing effect of the combination of two drugs was significantly higher than that of gefitinib alone. Conclusion Dasatinb combined with gefitinib can enhance the inhibition of Src family expression and enhance the killing effect of gefitinib on HCC827 lung cancer cells.